Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/18142Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Ntais, C. | en |
| dc.contributor.author | Polycarpou, A. | en |
| dc.contributor.author | Ioannidis, J. P. | en |
| dc.date.accessioned | 2015-11-24T18:50:45Z | - |
| dc.date.available | 2015-11-24T18:50:45Z | - |
| dc.identifier.issn | 1055-9965 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/18142 | - |
| dc.rights | Default Licence | - |
| dc.subject | Biological Markers | en |
| dc.subject | Cholestenone 5 alpha-Reductase/*genetics | en |
| dc.subject | Genotype | en |
| dc.subject | Humans | en |
| dc.subject | Male | en |
| dc.subject | Odds Ratio | en |
| dc.subject | *Polymorphism, Genetic | en |
| dc.subject | Prostatic Neoplasms/epidemiology/ethnology/*genetics | en |
| dc.subject | Risk Factors | en |
| dc.title | SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/12869400 | - |
| heal.identifier.secondary | http://cebp.aacrjournals.org/content/12/7/618.full.pdf | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2003 | - |
| heal.abstract | Several polymorphisms in the 5alpha-reductase type 2 (SRD5A2) gene have been implicated as risk factors for prostate cancer. We performed a meta-analysis of 9 studies (12 comparisons) with V89L genotyping (2558 prostate cancer cases and 3349 controls), 7 studies (8 comparisons) with A49T genotyping (1594 cases and 2137 controls), and 4 studies with TA repeat genotyping (1109 cases and 1378 controls). The random effects odds ratio (OR) for the L versus V allele was 1.02 [95% confidence interval (CI), 0.94-1.11]. There was no suggestion of an overall effect either in recessive or dominant modeling, and comparison of L/L versus V/V also showed no differential prostate cancer susceptibility (OR, 1.03; 95% CI, 0.83-1.28). The random effects OR for the T versus A allele was 1.56 (95% CI, 0.93-2.62). However, excluding the first published study there was no evidence for any effect (OR, 1.08; 95% CI, 0.72-1.61). Moreover, the T allele had a low prevalence (0%, 1%, and 2% in Asian, African and European controls, respectively). The random effects OR for longer versus short TA alleles was 0.88 (95% CI, 0.74-1.05). Longer TA allele homozygotes were nonsignificantly under-represented among prostate cancer cases (OR, 0.53; 95% CI, 0.26-1.06). We exclude a role for the V89L polymorphism in conferring susceptibility to prostate cancer. The A49T and TA repeat polymorphisms may have a modest effect on prostate cancer susceptibility, but bias and chance findings cannot be excluded; any genuine genetic effects would account only for a small proportion of prostate cancer in the population. | en |
| heal.journalName | Cancer Epidemiol Biomarkers Prev | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Ntais-2003-SRD5A2 gene polymorp.pdf | 89.17 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
